Showing results (1-10 of 142) with videos related to

Sort By:
Pageof 15
Circulation|June 1, 1983
What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experienceC D Furberg, R P Byington
Cardiovascular Clinics|January 1, 1989
Beta-adrenergic blockers in patients with acute myocardial infarctionC D Furberg, R P Byington
The American Journal of Medicine|April 17, 1989
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research GroupC D Furberg, R P Byington, N A Borhani
Atherosclerosis|July 25, 1998
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials dataJ R Crouse, R P Byington, C D Furberg
The American Journal of Cardiology|June 1, 1990
Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experienceR P Byington, J Worthy, T Craven, et al.
BMJ (Clinical Research Ed.)|April 7, 1990
Long term propranolol treatment and changes in body weight after myocardial infarctionS Rössner, C L Taylor, R P Byington, et al.
Archives of Internal Medicine|June 23, 1997
Reductase inhibitor monotherapy and stroke preventionJ R Crouse, R P Byington, H M Hoen, et al.
Diabetes Care|December 5, 1998
Isradipine in prediabetic hypertensive subjectsR P Byington, C D Furberg, T E Craven, et al.
The American Journal of Cardiology|September 28, 1995
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary ArteriesC D Furberg, B Pitt, R P Byington, et al.
Clinical Pharmacology and Therapeutics|November 1, 1985
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack TrialT Walle, R P Byington, C D Furberg, et al.
Pageof 15